Sanofi finds itself in the midst of a snowballing crisis in the Philippines over its dengue vaccine, Dengvaxia, after the Southeast Asian country said that the product may be related to some deaths. But the French multinational has declined to refund Manila the amount spent on its public dengue vaccination program and turned down a request for an indemnification fund.
Things appear to have escalated sharply after the Philippines said that an expert panel formed to probe if Dengvaxia was connected to the deaths of 14 children who were vaccinated with
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
